Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors

被引：144
|
作者：
Chia, Puey Ling [1 ]
Mitchell, Paul [1 ]
Dobrovic, Alexander [2 ,3 ,4 ]
John, Thomas [1 ,2 ,4 ]
机构：
[1] Olivia Newton John Canc & Wellness Ctr, Dept Med Oncol, Heidelberg, Vic, Australia
[2] Austin Hlth, Ludwig Inst Canc Res, Melbourne, Vic, Australia
[3] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia
[4] La Trobe Univ, Sch Canc Med, Bundoora, Vic 3086, Australia
来源：
CLINICAL EPIDEMIOLOGY | 2014年 / 6卷
关键词：
anaplastic lymphoma kinase (ALK); gene rearrangements; lung cancer; kinase inhibitors; lung adenocarcinoma; ANAPLASTIC LYMPHOMA KINASE; POLYMERASE CHAIN-REACTION; EML4-ALK FUSION VARIANTS; ACQUIRED-RESISTANCE; NEVER-SMOKERS; MOLECULAR CHARACTERIZATION; BRAF GENE; EGFR; MUTATIONS; IMMUNOHISTOCHEMISTRY;
D O I：
10.2147/CLEP.S69718
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%-5% of all NSCLC patients. ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably develops after several months of treatment. There are now several newer ALK inhibitors, with the next generation of agents targeting resistance mutations. In this review, we will discuss the prevalence and clinical characteristics of ALK+ lung cancer, current treatment options, and future directions in the management of this subset of NSCLC patients.
引用
收藏
页码：423 / 432
页数：10
相关论文
共 50 条
  • [21] Tackling ALK in non-small cell lung cancer: the role of novel inhibitors
    Facchinetti, Francesco
    Tiseo, Marcello
    Di Maio, Massimo
    Graziano, Paolo
    Bria, Emilio
    Rossi, Giulio
    Novello, Silvia
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (03) : 301 - 321
  • [22] An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer
    Ai, Xinghao
    Shen, Shengping
    Shen, Lan
    Lu, Shun
    BIOCHIMIE, 2015, 112 : 111 - 120
  • [23] Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
    Ali, Robert
    Arshad, Junaid
    Palacio, Sofia
    Mudad, Raja
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 569 - 580
  • [24] Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer
    Rosenbaum, Jason N.
    Bloom, Ryan
    Forys, Jason T.
    Hiken, Jeff
    Armstrong, Jon R.
    Branson, Julie
    McNulty, Samantha
    Velu, Priya D.
    Pepin, Kymberlie
    Abel, Haley
    Cottrell, Catherine E.
    Pfeifer, John D.
    Kulkarni, Shashikant
    Govindan, Ramaswamy
    Konnick, Eric Q.
    Lockwood, Christina M.
    Duncavage, Eric J.
    MODERN PATHOLOGY, 2018, 31 (05) : 791 - 808
  • [25] Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer
    Yoshida, Tatsuya
    Oya, Yuko
    Tanaka, Kosuke
    Shimizu, Junichi
    Horio, Yoshitsugu
    Kuroda, Hiroaki
    Sakao, Yukinori
    Hida, Toyoaki
    Yatabe, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) : 3383 - +
  • [26] Detection of Circulating Tumor Cells Harboring a Unique ALK Rearrangement in ALK-Positive Non-Small-Cell Lung Cancer
    Pailler, Emma
    Adam, Julien
    Barthelemy, Amelie
    Oulhen, Marianne
    Auger, Nathalie
    Valent, Alexander
    Borget, Isabelle
    Planchard, David
    Taylor, Melissa
    Andre, Fabrice
    Soria, Jean Charles
    Vielh, Philippe
    Besse, Benjamin
    Farace, Francoise
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18) : 2273 - +
  • [27] Initial Diagnosis of ALK-Positive Non-Small-Cell Lung Cancer Based on Analysis of ALK Status Utilizing Droplet Digital PCR
    Lund, H. Louise
    Hughesman, Curtis B.
    Fakhfakh, Kareem
    McNeil, Kelly
    Clemens, Shahira
    Hocken, Kimberly
    Pettersson, Ryan
    Karsan, Aly
    Foster, Leonard J.
    Haynes, Charles
    ANALYTICAL CHEMISTRY, 2016, 88 (09) : 4879 - 4885
  • [28] ALK inhibitors and advanced non-small cell lung cancer (Review)
    Rossi, Antonio
    Maione, Paolo
    Sacco, Paola Claudia
    Sgambato, Assunta
    Casaluce, Francesca
    Ferrara, Marianna Luciana
    Palazzolo, Giovanni
    Ciardiello, Fortunato
    Gridelli, Cesare
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (02) : 499 - 508
  • [29] New treatment options for ALK plus advanced non-small-cell lung cancer: critical appraisal of ceritinib
    Rothschild, Sacha I.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 735 - 741
  • [30] Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer
    Baik, Christina S.
    Chamberlain, Marc C.
    Chow, Laura Q.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : 1268 - 1278
12345